A prospective observational study to evaluate the quality of life and the costs in a real life setting in patients who are treated with 90Y-Zevalin
The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with model-predicted data at reimbursement on the basis of a clinical trial in heavily pre-treated NHL.
- Advanced cancer of the lymph nodes of follicular type at study inclusion - The patient has relapsed or has refractory disease, after previous treatment with rituximab - Treating physician has decided to treat the patient with a 90Y-Zevalin regimen - The patient is >= 18 years of age - Patient has given informed consent
- Patient is unwilling or unable to give informed consent - Patient is participating in another clinical trial
Many Locations, Belgium
E-mail: [email protected]
Phone: Not Available
A prospective observational study to evaluate quality of life and costs in a real life setting in patients treated with 90Y-Zevalin